Identification of a JAK2 mutation in Polycythemia Vera
View Patent ↗The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
1. An in vitro method to determine the presence of the G1849T mutation in the JAK2 gene in a human patient comprising:
a) obtaining and analyzing a nucleic acid sample from the human patient;
b) detecting a T in the JAK2 gene at position 2343 of SEQ ID No 2 in the sample; and
c) recording the presence of a T in the JAK2 gene at position 2343 of SEQ ID No 2 in the sample.
2. An in vitro method to determine if a human patient is currently suffering from or is likely to develop a myeloproliferative disorder selected from the group consisting of Polycythemia Vera, essential thrombocythemia, and idiopathic myelofibrosis comprising:
a) obtaining and analyzing a nucleic acid sample from the human patient;
b) detecting a T in the JAK2 gene at position 2343 of SEQ ID No 2 in the sample; and
c) recording the presence of a T in the JAK2 gene at position 2343 of SEQ ID No 2 in the sample; wherein the presence of a T at position 2343 of SEQ ID No 2 indicates the human patient is currently suffering from or is likely to develop a myleoproliferative disorder selected from the group consisting of Polycythemia Vera, essential thrombocythemia, and idiopathic myelofibrosis.
3. The method of claim 1 , wherein the analyzing comprises:
a) sequencing a region of the nucleic acid sample comprising position 2343 of SEQ ID No 2; or
b) hybridizing under stringent conditions the nucleic acid sample with at least one probe comprising at least 10 consecutive nucleotides of SEQ ID No 2 comprising position 2343 of SEQ ID No 2.
4. The method of claim 1 , wherein analyzing comprises amplifying a region of the nucleic acid sample comprising position 2343 of SEQ ID No 2 with at least one primer and hybridizing under stringent conditions the nucleic acid sample with at least one probe comprising at least 10 consecutive nucleotides of SEQ ID No 2 comprising position 2343 of SEQ ID No 2.
5. The method of claim 3 , wherein the at least one probe is labeled with at least one marker and detecting comprises detection of the signal produced by the at least one probe.
6. The method of claim 5 , wherein the hybridizing comprises hybridizing with at least two probes.
7. The method of claim 4 , wherein the nucleic acid sample is mRNA and wherein amplifying comprises amplifying by reverse transcriptase-polymerase chain reaction.